JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

BACKGROUND: Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor of JAK1 and JAK2. This study tested the efficacy of baricitinib versus placebo on albuminuria in adults with Type 2 diabetes at hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuttle, Katherine R, Brosius, Frank C, Adler, Sharon G, Kretzler, Matthias, Mehta, Ravindra L, Tumlin, James A, Tanaka, Yoshiya, Haneda, Masakazu, Liu, Jiajun, Silk, Maria E, Cardillo, Tracy E, Duffin, Kevin L, Haas, Joseph V, Macias, William L, Nunes, Fabio P, Janes, Jonathan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212720/
https://www.ncbi.nlm.nih.gov/pubmed/29481660
http://dx.doi.org/10.1093/ndt/gfx377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212720/
https://www.ncbi.nlm.nih.gov/pubmed/29481660
http://dx.doi.org/10.1093/ndt/gfx377

Ejemplares similares